A Study to Evaluate the Efficacy and Safety of ALH-L1005 in Patients With Chronic Periodontitis

NCT04503746 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Periodontitis

Interventions

DRUG: ALH-L1005 600mg/day
DRUG: ALH-L1005 1,200mg/day
DRUG: Placebo

Sponsor

AngioLab, Inc.